<DOC>
	<DOCNO>NCT02870348</DOCNO>
	<brief_summary>This multi-center , open-label study evaluate long-term safety weekly IV infusion 60 mg/kg Alpha-1 MP adult subject AATD Japan complete Study GTI1401 .</brief_summary>
	<brief_title>Long-term Safety Alpha1-Proteinase Inhibitor ( Human ) Japanese Subjects With Alpha1 Antitrypsin Deficiency ( GTI1401-OLE )</brief_title>
	<detailed_description>This multi-center , open-label study evaluate long-term safety weekly IV infusion 60 mg/kg Alpha-1 MP adult subject AATD Japan complete Study GTI1401 . Study GTI1401 conduct evaluate safety PK Alpha-1 MP subject AATD Japan . In current study , GTI1401-OLE , subject administer 60 mg/kg Alpha-1 MP weekly IV infusion approximately 1 year ( renew annually consent subject unless sponsor informs discontinuation OLE trial ) ass long-term safety Alpha-1 MP subject AATD . This study conduct 5 center Japan . At Week 9 Visit Study GTI1401 , give consent , day , subject assess eligibility Screening/Extention ( Ext ) Week 1 Visit extension study , Study GTI1401-OLE . If eligible , subject administer weekly IV infusion 60 mg/kg Alpha-1 MP approximately 1 year longer . The Week 9 Visit GTI1401 End Study Visit subject enrol Study GTI1401-OLE . Subjects Study GTI1401-OLE option remain Study GTI1401-OLE continue receive weekly IV infusion 60 mg/kg Alpha-1 MP another year longer . If subject plan conclude participation study ( GTI1401-OLE ) early ( Ext . Week 52 ) , ask complete End Study Follow-Up Assessments , schedule 4 week last infusion .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Subjects complete participation Study GTI1401 ( i.e. , complete study Week 9 Visit ) . Subjects able provide write informed consent . Subjects newly diagnose severe concomitant disease include , limited , congestive heart failure liver cirrhosis . Subjects newly diagnose malignant tumor ( include malignant melanoma ; however , form skin cancer allow ) . Female subject pregnant , breastfeeding , childbearing potential , unwilling practice highly effective method contraception ( oral , injectable implanted hormonal method contraception , placement intrauterine device [ IUD ] intrauterine system [ IUS ] , condom occlusive cap spermicidal foam/gel/film/cream/suppository , male sterilization , abstinence ) throughout study male subject partner childbearing potential unwilling practice highly effective method contraception throughout study . Subjects clinical sign symptom active HAV , HBV , HCV , HIV viral infection Week 9 Visit Study GTI1401 viral infection confirm test . Subjects current evidence smoking positive urine cotinine test Week 9 Visit Study GTI1401 due smoking . Subjects currently participate study another investigational product ( Alpha1 MP ) . Subjects difficulty adhere protocol procedure , opinion investigator . Subjects medical condition may confound result clinical trial may endanger subject participation clinical trial opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>